306 related articles for article (PubMed ID: 32720769)
21. Development of Cancer Immunotherapy Targeting the PD-1 Pathway.
Kamimura N; Wolf AM; Iwai Y
J Nippon Med Sch; 2019; 86(1):10-14. PubMed ID: 30918149
[TBL] [Abstract][Full Text] [Related]
22. Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance.
Geraud A; Gougis P; Vozy A; Anquetil C; Allenbach Y; Romano E; Funck-Brentano E; Moslehi JJ; Johnson DB; Salem JE
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():85-112. PubMed ID: 32871087
[TBL] [Abstract][Full Text] [Related]
23. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint blockade therapy: the 2014 Tang Prize in Biopharmaceutical Science.
Chen YS; Shen CR
Biomed J; 2015; 38(1):5-8. PubMed ID: 25673064
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; MĂ©kinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
26. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
Shergold AL; Millar R; Nibbs RJB
Pharmacol Res; 2019 Jul; 145():104258. PubMed ID: 31063806
[TBL] [Abstract][Full Text] [Related]
27. [Management of toxicities from immunotherapy].
Heinrich K; von Bergwelt-Baildon M; Theurich S
Dtsch Med Wochenschr; 2021 Sep; 146(17):1119-1128. PubMed ID: 34448188
[TBL] [Abstract][Full Text] [Related]
28. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
29. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
Lee HT; Lee SH; Heo YS
Molecules; 2019 Mar; 24(6):. PubMed ID: 30917623
[TBL] [Abstract][Full Text] [Related]
30. [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition].
Benesova K; Leipe J
Z Rheumatol; 2020 Aug; 79(6):545-553. PubMed ID: 32613268
[TBL] [Abstract][Full Text] [Related]
31. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
32. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
Li K; Tian H
J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
[TBL] [Abstract][Full Text] [Related]
33. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
[TBL] [Abstract][Full Text] [Related]
34. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
35. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
[TBL] [Abstract][Full Text] [Related]
36. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
Nadeau BA; Fecher LA; Owens SR; Razumilava N
Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
[TBL] [Abstract][Full Text] [Related]
37. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients.
Cortellini A; Buti S; Agostinelli V; Bersanelli M
Semin Oncol; 2019; 46(4-5):362-371. PubMed ID: 31727344
[TBL] [Abstract][Full Text] [Related]
38. [Not Available].
Senant M; Giusti D; Weiss L; Dragon-Durey MA
Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
[TBL] [Abstract][Full Text] [Related]
39. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]